⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TGTX News
TG Therapeutics, Inc.
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
prnewswire.com
GILD
INCY
BIIB
NVS
AMGN
JNJ
ABBV
BMY
AZN
MRK
PFE
TGTX
XNCR
CABA
IMUX
ZNTL
GLPG
CLNN
AUTL
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
globenewswire.com
TGTX
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
globenewswire.com
TGTX
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
globenewswire.com
TGTX
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
globenewswire.com
TGTX
Tangram Therapeutics annonce l’administration de la première dose à un participant dans le cadre de l’essai RESTORE-MASH de phase I/II portant sur le TGM-312, un nouveau médicament expérimental à base d’ARNi
globenewswire.com
TGTX
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
businesswire.com
TGTX
DTIL
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
businesswire.com
DTIL
TGTX
Form 8-K
sec.gov
TGTX
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
globenewswire.com
TGTX